🚀 VC round data is live in beta, check it out!
Tempest Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Tempest Therapeutics and similar public comparables like Molecure, Elicera Therapeutics, Marker Therapeutics, BioXcel Therapeutics and more.
Tempest Therapeutics Overview
About Tempest Therapeutics
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Founded
2011
HQ
Employees
25
Website
Sectors
Financials (LTM)
EV
$30M
Tempest Therapeutics Financials
Tempest Therapeutics reported last 12-month revenue of — and negative EBITDA of ($25M).
In the same LTM period, Tempest Therapeutics generated — in gross profit, ($25M) in EBITDA losses, and had net loss of ($25M).
Revenue (LTM)
Tempest Therapeutics P&L
In the most recent fiscal year, Tempest Therapeutics reported revenue of — and EBITDA of ($26M).
Tempest Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($25M) | XXX | ($26M) | XXX | XXX | XXX |
| Net Profit | ($25M) | XXX | ($26M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Tempest Therapeutics Stock Performance
Tempest Therapeutics has current market cap of $29M, and enterprise value of $30M.
Market Cap Evolution
Tempest Therapeutics' stock price is $2.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $30M | $29M | 29.7% | XXX | XXX | XXX | $-1.83 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTempest Therapeutics Valuation Multiples
Tempest Therapeutics trades at (1.2x) EV/EBITDA.
Tempest Therapeutics Financial Valuation Multiples
As of April 11, 2026, Tempest Therapeutics has market cap of $29M and EV of $30M.
Equity research analysts estimate Tempest Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tempest Therapeutics has a P/E ratio of (1.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $29M | XXX | $29M | XXX | XXX | XXX |
| EV (current) | $30M | XXX | $30M | XXX | XXX | XXX |
| EV/EBITDA | (1.2x) | XXX | (1.2x) | XXX | XXX | XXX |
| EV/EBIT | (1.2x) | XXX | (1.1x) | XXX | XXX | XXX |
| P/E | (1.2x) | XXX | (1.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tempest Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Tempest Therapeutics Margins & Growth Rates
Tempest Therapeutics' revenue in the last fiscal year grew by —.
Tempest Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.1M for the same period.
Tempest Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | (16%) | XXX | (21%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Tempest Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Molecure | XXX | XXX | XXX | XXX | XXX | XXX |
| Elicera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Marker Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| BioXcel Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Intervacc | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tempest Therapeutics M&A Activity
Tempest Therapeutics acquired XXX companies to date.
Last acquisition by Tempest Therapeutics was on XXXXXXXX, XXXXX. Tempest Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Tempest Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTempest Therapeutics Investment Activity
Tempest Therapeutics invested in XXX companies to date.
Tempest Therapeutics made its latest investment on XXXXXXXX, XXXXX. Tempest Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Tempest Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tempest Therapeutics
| When was Tempest Therapeutics founded? | Tempest Therapeutics was founded in 2011. |
| Where is Tempest Therapeutics headquartered? | Tempest Therapeutics is headquartered in United States. |
| How many employees does Tempest Therapeutics have? | As of today, Tempest Therapeutics has over 25 employees. |
| Who is the CEO of Tempest Therapeutics? | Tempest Therapeutics' CEO is Matthew Angel. |
| Is Tempest Therapeutics publicly listed? | Yes, Tempest Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Tempest Therapeutics? | Tempest Therapeutics trades under TPST ticker. |
| When did Tempest Therapeutics go public? | Tempest Therapeutics went public in 2021. |
| Who are competitors of Tempest Therapeutics? | Tempest Therapeutics main competitors are Molecure, Elicera Therapeutics, Marker Therapeutics, BioXcel Therapeutics. |
| What is the current market cap of Tempest Therapeutics? | Tempest Therapeutics' current market cap is $29M. |
| Is Tempest Therapeutics profitable? | No, Tempest Therapeutics is not profitable. |
| What is the current EBITDA of Tempest Therapeutics? | Tempest Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Tempest Therapeutics? | Current EBITDA multiple of Tempest Therapeutics is (1.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.